Literature DB >> 32478733

Generation of Human Regulatory T Cell Clones.

Johannes Nowatzky1, Olivier Manches2.   

Abstract

Human regulatory T cells (Treg) are notoriously difficult to isolate in high purity given the current methods of Treg enrichment. These methods are based on the identification of Treg through several activation-dependent cellular surface markers with varying expression levels in different physiologic and pathologic conditions. Populations isolated as "Treg" therefore often contain considerable numbers of non-Treg effector cells (i.e., Teff) which hamper the precise phenotypic and functional characterization of these cells, their genomic and proteomic characterization, their reliable enumeration in different states of health and disease, as well as their isolation and expansion for therapeutic purposes. The latter, in particular, remains a major hurdle, as the inadvertent expansion of effector cells homing in Treg-relevant cellular compartments (e.g., CD4+CD25+ T cells) may render Treg-based immunotherapy ineffective, or even harmful. This work presents a method that circumvents the problems associated with population-based isolation and expansion of Treg and shows that the generation of Treg candidate clones with the subsequent selection, culture, and expansion of only carefully vetted, monoclonal cells, enables the generation of an ultrapure Treg cell product that can be kept in culture for many months, enabling downstream investigation of these cells, including for possible therapeutic applications.

Entities:  

Year:  2020        PMID: 32478733     DOI: 10.3791/61075

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  1 in total

1.  Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity.

Authors:  Ann Cavers; Matthias Christian Kugler; Yesim Ozguler; Arshed Fahad Al-Obeidi; Gulen Hatemi; Beatrix M Ueberheide; Didar Ucar; Olivier Manches; Johannes Nowatzky
Journal:  Ann Rheum Dis       Date:  2022-08-03       Impact factor: 27.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.